CAR T cells against CD19 antigen and B-cell maturation antigen (BCMA) have been approved to treat refractory diffuse large B-cell lymphoma (DLBCL), ALL, and MM [12–15]. Here, TNFRSF17 is linked to diffuse large B-cell lymphoma.